Cathy Yeulet/Getty Images Taking money out of your 401(k) before age 59½ typically results in taxes and penalties on the amount withdrawn. Investors who take early withdrawals also miss out on the tax-deferred growth their savings would have accumulated if they had left the money in the 401(k) plan or rolled it over to an individual retirement account. Here's what happens when you take an early 401(k) withdrawal and how to limit the fallout. Income tax. Regular income tax is due on each withdrawal from your traditional 401(k) plan. A worker in the 25 percent tax bracket who withdraws $10,000 from a 401(k) plan will owe $2,500 in federal income taxes on it, and perhaps more in state income taxes. When you receive a 401(k) distribution, 20 percent will typically be withheld for income tax purposes. So, when you withdraw $10,000 from a 401(k) account, you will actually only receive $8,000. You will need to come up with any additional tax you owe from the distribution itself or another source. "Many people who have cash-outs when they leave a job often are not leaving their job voluntarily, and some of this is being used as a temporary stopgap measure," says Jack VanDerhei, research director of the Employee Benefit Research Institute. "If you have a situation where you don't absolutely have to have the money, you should keep as much in the tax-advantaged accounts as possible."
Top 5 Logistics Companies To Invest In 2015: Amdocs Limited (DOX)
Amdocs Limited, together with its subsidiaries, provides software and services for communications, media, and entertainment industry service providers worldwide. It offers revenue management products, including convergent charging and billing, mediation, partner management, service delivery, compact convergence, and machine-to-machine solutions that manage the end-to-end network services revenue stream from offer definition to cash-in-hand and spans the consumer, business, and partner domains. The company also provides customer management products comprising multichannel selling, multichannel care, and proactive insight products that enable service providers to simplify the customer experience in all interaction channels and touch points; operations support systems, such as network planning, service fulfillment, service assurance, inventory and discovery, business service capture, network navigator, and radio parameter manager for fixed line, wireless, and cable networks; and network control products consisting of service controllers, home subscriber servers, policy controllers, data and Wi-Fi experience solutions, and intelligent diameter routing agents. In addition, it offers digital services, which include connected home solutions, mobile payments, digital commerce solutions, personalization, and unified communications and foundation. Further, the company provides advertising and media solutions that comprise sales experience, business agility, small-medium business experience, and business content and advertising syndication solutions. Additionally, it offers business consulting, system integration, information technology outsourcing and value process operation managed services, managed transformation, and product support services. Amdocs Limited was founded in 1988 and is based in St. Peter Port, Channel Islands.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Amdocs (NYSE: DOX ) , whose recent revenue and earnings are plotted below.
Hot Heal Care Stocks To Own Right Now: Primerica Inc.(PRI)
Primerica, Inc., together with its subsidiaries, engages in the distribution of financial products on behalf of third parties to middle income households in the United States and Canada. The company operates in three segments: Term Life Insurance, Investment and Savings Products, and Corporate and Other Distributed Products. The Term Life Insurance segment underwrites term life insurance products. The Investment and Savings Products segment distributes mutual funds, variable annuities, fixed annuities, and segregated funds. The Corporate and Other Distributed Products segment provides mortgage loans, which include debt consolidation or refinance, and purchase money loans; unsecured loans; prepaid legal services that assist subscribers with legal matters, such as drafting wills, living wills and powers of attorney, trial defense, and motor vehicle-related matters; mail-order student life products; short-term disability benefit insurance; and auto and homeowners? insurance products. The company was founded in 1927 and is based in Duluth, Georgia.
Advisors' Opinion:- [By Rich Duprey]
Private equity investor Warburg Pincus has been a shareholder in term life insurance underwriter Primerica� (NYSE: PRI ) since its IPO in 2010. However, the financial products marketer will be buying back all of the holdings Warburg Pincus owns for $154.7 million. That translates into�almost�2.5 million shares of common stock�and warrants that �are�exercisable for 4.1 million shares.
Hot Heal Care Stocks To Own Right Now: Lithia Motors Inc. (LAD)
Lithia Motors, Inc. operates as an automotive franchisee and retailer of new and used vehicles in the United States. The company sells new and used cars, and trucks; offers replacement parts; provides vehicle maintenance, warranty, paint, and repair services; and arranges related financing, service contracts, protection products, and credit insurance. As of February 22, 2013, the company offered 27 brands of new vehicles and various brands of used vehicles in 87 stores, as well as online at Lithia.com. Lithia Motors, Inc. was founded in 1946 and is based in Medford, Oregon.
Advisors' Opinion:- [By Inyoung Hwang]
Ladbrokes (LAD) rallied 2.9 percent to 185 pence, posting the biggest two-day gain since April 2009. A mystery buyer, thought to be Sagi, bought a stake in the U.K. bookmaker, the Telegraph reported. The deal, through Shore Capital, was just below the 3 percent disclosure limit, according to the Telegraph. The purchase fueled speculation about a possible bid, the newspaper said.
- [By ovenerio]
The company has a current ROE of 14.85% which is higher than the industry median. In general, analysts consider ROE ratios in the 15-20% range as representing attractive levels for investment. So for investors looking those levels or more, AutoNation (AN), CST Brands (CST), Lithia Motors (LAD) and AutoZone (AZO) could be the options. It is very important to understand this metric before investing and it is important to look at the trend in ROE over time.
- [By Ben Levisohn]
Lithia Motors (LAD) fell8.3% to $63.31 despite beating earnings forecasts on lower guidance.
Monarch Casino & Resort (MCRI) fell 15% to $18.71 after revenue missed forecasts today.
- [By Corinne Gretler]
Fresnillo Plc soared 6.6 percent to a two-month high as precious metals gained. Prudential Plc climbed to the highest in more than two decades after posting a 22 percent jump in profit. Telekom Austria AG dropped 1.6 percent after reporting second-quarter earnings that missed analysts��projections. Ladbrokes Plc (LAD) slid 2.6 percent as JPMorgan Chase & Co. downgraded the U.K. gambling company.
Hot Heal Care Stocks To Own Right Now: Boston Therapeutics Inc (BTHE)
Boston Therapeutics, Inc. is a development-stage company. The Company�� business is the development, manufacture and commercialization of therapeutic drugs and dietary supplements with a focus on glyco-pathology, a specialized field involving understanding the importance of carbohydrates in biochemistry and progression of diseases. The Company is focusing on three products: IPOXYN, an injectable anti-hypoxia drug, which it is developing; PAZ320, which is a non-systemic, chewable drug candidate for reduction of blood glucose in diabetics in development and SUGARDOWN, a complex carbohydrate-based chewable dietary supplement, which it is marketing. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the class of carbohydrate-hydrolyzing enzyme inhibitors.
SUGARDOWN
The Company has developed SUGARDOWN, a non-systemic complex carbohydrate-based dietary supplement to moderate post-meal blood glucose using processes and technology. It has unrestricted access to both sufficient raw materials at commodity pricing and processing facilities to produce sufficient supply of SUGARDOWN to support product distribution across multiple sales channels as a dietary supplement. Its SUGARDOWN dietary supplement consists of a stabilized complex carbohydrate composition. The Company has completed development of SUGARDOWN as a dietary supplement. On January 24, 2012 the Company announced the clinical trial results in healthy volunteers performed at the University of Sydney on SUGARDOWN.
PAZ320
PAZ320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes, which release glucose from complex carbohydrate in foods during digestion, reducing the amount of available glucose absorbed through the intestine. PAZ320 is in development as a drug candidate. The Company�� non-systemic compounds for prediabetes and diabetes, SUGARDOWN and PAZ320, belong to the! class of carbohydrate-hydrolyzing enzyme inhibitors.
IPOXYN
The Company has developed a drug candidate product IPOXYN, a glyco-protein based therapeutic agent. Its IPOXYN anti-hypoxia drug consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support. In addition to potential uses for human patients, it also focuses to file a registration for IPOXYN for veterinary applications under the name OXYFEX. The Company�� pharmaceutical agents are intended for intravenous administration into the circulatory system to target acute and late stage diseases.
Advisors' Opinion:- [By CRWE]
Today, BTHE remains (0.00%) +0.000 at $1.10 thus far (ref. google finance Delayed: 12:25PM EDT October 10, 2013).
Boston Therapeutics has previously closed the final tranche of approximately $1.8 million to bring total gross proceeds of approximately $5.3 million from the private placement of Common Stock and warrants to existing and new accredited investors (the “Offering”).
Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes. PAZ320 is the first compound in a new class of therapies for this disease.
No comments:
Post a Comment